United States: OIG Advisory Opinion 15-07: An Indicator Of Clinical Trial Copayment Change?

Last Updated: June 23 2015
Article by Payal P. Cramer and Gregory E. Fosheim

"You scratch my back, I scratch yours" arrangements are common in business transactions. These agreements are risky in the healthcare space, however, with the potential to implicate civil and criminal sanctions. Whether involving a patient, provider, or industry, the government closely scrutinizes quid pro quo arrangements when the government foots the bill.

Clinical trial sponsors often have motivation to cover copayment obligations of trial enrollees. Sponsor coverage of copayments allows subjects to participate in trials without incurring costs directly, while permitting sponsors to minimize trial costs by relying on insurance coverage of routine items and services instead of conducting fully sponsor-paid research. Such practice can raise regulator concerns when trial subjects are also beneficiaries of federal healthcare programs.

In a 2002 Special Advisory Bulletin, the U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG) focused on waivers of copayments and deductibles in clinical trials where well-established treatments were already available. While acknowledging the advantages of copayment and deductible waivers for patients, the Special Advisory Bulletin noted that when sponsors waive cost-sharing obligations to encourage subjects to participate in such trials, the sponsors may actually induce subjects to forgo equally effective or more appropriate nonexperimental care.

Since 2002, the OIG has contemplated soliciting public comments on establishing a regulatory safe harbor to the anti-kickback statute for free goods and services (including copayment waivers) provided to beneficiaries in connection with clinical trials sponsored at least in part by the National Institutes of Health or other governmental organizations. To date, no such request for comments has been issued. Instead, clinical trial sponsors who wish to cover copayments of Medicare beneficiaries subject themselves to OIG scrutiny.

In early June, the OIG again published an Advisory Opinion addressing copayment waivers in the clinical trial setting. Advisory Opinion 15-07 represents the first time the OIG has explicitly indicated that it will not impose civil monetary penalties or administrative sanctions for an arrangement whereby a commercial trial sponsor may routinely cover the copayment obligation of clinical trial enrollees who are also Medicare beneficiaries and provide other subsidies for participation in the trial. It is yet to be determined whether this Advisory Opinion suggests a sea change in the government's position or simply demonstrates a narrow set of facts where such remuneration arrangements are permitted.


Advisory Opinion 15-07 provides an analysis and enforcement decision on a medical device manufacturer's request to waive copayments and offer related subsidies for Medicare beneficiaries who participate in a clinical trial involving the manufacturer's product. The product is designed to assist in performing a type of minimally invasive spinal surgery known as percutaneous image-guided lumbar decompression for lumbar spinal stenosis (PILD). The manufacturer's request arose from the particular, and less common, coverage mechanism applicable to the product.

Generally, for Medicare to cover an item or service for its beneficiaries, CMS must find the item or service to be "reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member." (42 U.S.C. 1395y(a)(1)(A)). CMS typically makes this determination by conducting a National Coverage Determination (NCD), which involves discussion of relevant medical and scientific information and request for public comment.

In the NCD for PILD, CMS determined that the procedure was not "reasonable and necessary" for blanket coverage authorization. Instead, CMS agreed to cover PILD through the Coverage with Evidence Development Program, a mechanism by which CMS may support innovative technologies that may benefit Medicare beneficiaries but the basis for coverage requires more data (in the form of a clinical trial) before CMS is persuaded of its reasonable and necessary nature. CMS coverage was limited to beneficiaries enrolled in certain clinical trials meeting specified criteria. Specifically, the clinical trial must answer whether PILD (1) provides a clinically meaningful improvement of function and/or quality of life compared with other treatments, (2) provides clinically meaningful reduction in pain compared with other treatments, or (3) affects the overall clinical management and decision making, including use of other medical treatments or services, compared with other treatments. CMS required that the clinical trial utilize a randomized, controlled design with appropriate comparator treatments or a sham controlled arm.

Proposed Clinical Trial and Copayment Coverage

Under CMS's trial parameters and with CMS's input, the manufacturer developed a clinical trial to evaluate the effectiveness of PILD using its product compared with a sham procedure. The trial design included prospective, multicenter, randomized, controlled, blinded measures with the goal of determining whether the manufacturer's product meaningfully improved health outcomes following PILD. Treatment group subjects would receive PILD with the manufacturer's product; control group subjects would receive sham surgery involving the same anesthesia and skin incision as the PILD group but with no therapeutic treatment.

Because the trial followed CMS's prescribed requirements, those subjects who were randomized to the treatment group and were enrolled in Medicare could have Medicare coverage for their PILD and would be subject to copayment through their insurance coverage. By comparison, those subjects randomized to the control arm would not be eligible for Medicare coverage because they would not receive a procedure with any therapeutic intent. Thus, billing Medicare and collecting a copayment from the subject would be prohibited. The manufacturer expressed concern that a failure to collect copayments from subjects randomized to the control arm would compromise the trial design – subjects would know their group by virtue of their copayment obligation. To prevent any unintended unblinding, the manufacturer sought to pay the copayments on behalf of Medicare beneficiaries enrolled on the treatment arm.

Further, during follow-up, any subject for whom the PILD is deemed a failure would be unblinded; those originally in the control group would be given the opportunity to undergo PILD using the manufacturer's product and at the manufacturer's expense. The manufacturer believed that subsidizing the PILD procedure for control group subjects was necessary to encourage trial enrollment despite the risk of being randomized to a sham surgery.

OIG's Analysis

The manufacturer's proposal involved two potential areas of improper remuneration: (1) paying copayments of Medicare beneficiaries randomized to the treatment arm, and (2) paying the costs of the PILD procedure for control group subjects. None of the regulatory exceptions available under the anti-kickback statute or the Civil Monetary Penalties Law applied to the proposed arrangement. Nevertheless, using the rationale below, the OIG determined that the manufacturer's proposed arrangement posed minimal risk of fraud and abuse under the anti-kickback statute:

  • The proposed arrangement would further CMS's policy objectives. The manufacturer designed the trial in consultation with CMS and in alignment with CMS's parameters. Any results would be shared with CMS to determine whether PILD is reasonable and necessary for broader Medicare coverage.
  • CMS required a randomized, controlled, blinded trial with appropriate comparator mechanisms. The manufacturer's proposed arrangement was reasonable to encourage trial enrollment and to properly assess the true impact of PILD using the manufacturer's product.
  • The manufacturer certified that the arrangement was independent of any other arrangement or agreement between or among manufacturer and investigators, trial sites, and trial participants. Further, any compensation paid was in conjunction with the fair market value for necessary trial services.
  • The risk of overutilization or increased costs to federal healthcare programs was minimized because subjects would be required to meet predetermined enrollment criteria and execute an informed consent document before participating in the trial, and investigators would be required to adhere to the trial protocol and report to an institutional review board.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions